Taivex Therapeutics Corporation (Taivex) and The National Health Research Institutes (NHRI) are pleased to announce the technology transfer of T-1201 (formerly, DBPR115), a potential anti-cancer developmental drug candidate, effective on Augest 18, 2016.This targeting drug, T-1201 could deliver the itself to the tumor site and make the drug accumulated at the tumor site. Increasing the drug concentration around the tumor so decrease the side effects. The preliminary results shows that the dose of DBPR115 was only 1/5 of the marketing drug, but the tumor inhibition effect was more than the marketing drug.

Taivex will carry out the preclinical and clinical development of T-1201 and advance its commercialization.